RCOphth Annual Congress
The ROYAL COLLEGE of OPHTHALMOLOGISTS
20-23 May 2024, ICC Belfast

Our Initial Real-World Outcome Of Faricimab (Vabysmo) In Treatment Experienced nAMD At CHFT

Ms Safaa Mahmoud , FRCOPHTH, CHFT, Ms Indra Dias , Medical Retinal Lead CHFT.

NHS
Calderdale And Huddersfield
NHS Foundation Trust

Introduction: a retrospective audit of 165 treatment experienced nAMD eyes treated with Faricimab from January 1st to September 1st, 2023, was conducted to assess outcomes and guide local/regional guidelines.

Method: utilizing data from Medisight and OCT scans, the study focused on injection patterns, OCT and clinical morphologic changes, and visual acuity at Baseline, Week 4 and Week 24.
The treatment protocol included switching previously treated nAMD eyes who are resistant, unstable on their current anti VEGF or requiring less than 8 weekly interval to stabilize.
Four loading injections were considered in eyes with more aggressive diseases. When stable treat and extend protocol (T&E) considered.

Pattern of injections (165 Eyes):

4 loading injections were considered in 92 eyes (56%) with unstable disease.	Previous injections ranged from 5 to 86 injections/eye, with mean of 30 injections.	Total of injections was 787, (Mean 4 inj./eye when no loading - & 5/eye when reloading - required)
Average interval between injections for all eyes was 7 weeks (Max 30)	T&E started in 103 eyes (62%), with mean injection interval of 10 weeks	100 eyes (61%) are now stable on an ≥8-weekly injection interval

Results at week 4 62% of eyes had dry macular OCT, 17% reduction in mean CRT (323 to 265 microns at week 4 and 24), and a positive trend in PED improvement.


Last visit outcomes demonstrated a mean ETDRS VA stable at 62 letters, with 68% experiencing vision gain or avoidance of vision loss. Notably, 46% maintained good vision up/near to driving standards.


The mean injection interval was 7 weeks, and 62% transitioned to T&E. 61% are now on or over 8 weekly interval.


One patient had CVA, three developed Geographic Atrophy with subsequent visual loss, two eyes showed poor response and switched to another anti VEGF, and one eye developed RPE rip.

The demographics of our sample included mean Age of 80 with 86% 75 years or older, 60% Females, & over 90% White Caucasian.

OCT Progression With Treatment








Change In BCVA With Treatment

- The mean baseline BCVA was 62 letters (range from 24 to 80 letters)
- The mean last visit BCVA was 62 letters (min 24 letters, max 82 letters)


	Loss BCVA	Stable BCVA	Gained BCVA	Stable or Gained BCVA
Count	53 eyes (32%)	78 eyes (47%)	34 eyes (21%)	112 eyes (68%)
Mean	-7 letters	0 letters	9 letters	3 letters
Min	-4 letters	-3 letters	4 letters	-3 letters
Max	-19 letters	3 letters	32 letters	32 letters





Discussion: In line with the NOD; 46% of eyes in our audit maintained good VA at or near to the driving standards.
- Saagar A etal, in their study on 191 eyes with previous anti VEGF treatment for nAMD switched to Faricimab, found that the mean VA before and after 4 Faricimab injections were around 60 letters, this was 62 in our study. The CRT improved from 354 to 306 um after switching (323um reduced to 265 um after switching in our study), a positive trend in PED flattening was also reported in their study.

Conclusion: In contrast to our audit on naive nAMD patients treated with Faricimab, the group with prior treatment exhibited lower vision gains, as anticipated given the more challenging and resistant disease nature. Nevertheless, more than 60% of these eyes successfully underwent T&E.
A subsequent project is essential to assess the long-term outcomes and stability.

Case 1 (Previous 56 injections):
OCT before & after first VABYSMO injection:
Great Morphological response, Yet the BCVA down from 72 to 63 letters, probably from the Atrophy.













Case 2 (40 previous injections): OCT after first VABYSMO injection
BCVA stable 68 letters





Case 3 (Previous 31 injections with poor response)
Vision up from 38 to 70 letters after 2 Vabysmo injections (but also had cataract surgery)





References:
- Faricimab for treating wet AMD, Technology appraisal guidance, June 2022, https://www.nice.org.uk/guidance/ta800/chapter/1-Recommendations.
- National Ophthalmology Database Audit The Second Report of AMD Audit, March 2024 https://nodaudit.org.uk/sites/default/files/2024-03/NOD%20AMD%20Audit%20Full%20Annual%20Report%202024_0.pdf
- Clinical Outcomes of Faricimab in Patients with Previously Treated nAMD, Saagar A. Pandit MD, MPH, https://doi.org/10.1016/j.oret.2023.10.018

Abbreviations Key: nAMD: neovascular age-related macular degeneration; CHFT: Calderdale and Huddersfield NHS Foundation Trust; OCT: Optical Coherence Tomography; T&E: Treat and Extend Protocol; PED: pigment epithelial detachment; CRT: Central Retinal Thickness; PED: Pigment Epithelial Detachment; RPE: retinal pigment epithelium; ETDRS: Early Treatment Diabetic Retinopathy Letters Vision Chart; VA: Visual Acuity; um: Micron; IRF, intraretinal fluid; SRF, subretinal fluid; BCVA: Best Corrected Visual Acuity; AI: Artificial Intelligence.

Declaration: The first author was sponsored to present the outcome of this study at the Yorkshire Vabysmo meeting in Nov 2023.